Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFenner PLC Regulatory News (FENR)

  • There is currently no data for FENR

Acquisition

2 Feb 2015 07:00

RNS Number : 6949D
Fenner PLC
02 February 2015
Β 

02 February 2015

Fenner PLC ("Fenner")

Acquisition of Charter Medical Limited ("Charter")

Fenner is pleased to announce that its wholly owned subsidiary Fenner Drives, Inc. has acquired 100% of the share capital of Charter from its parent company Lydall, Inc. a publicly traded company (NYSE: LDL) headquartered in Connecticut. Charter will be integrated into Solesis Medical Technologies ("Solesis"), part of Fenner's AEP division.

The consideration of US$29.9m was satisfied in cash at completion and the transaction is expected to be earnings enhancing immediately upon acquisition.

Charter manufactures specialty single-use assemblies and Class I and Class II medical devices for the collection, processing, storage and filtration of biological and bioprocessing fluids. Charter also produces bio-containers and fluid management sets that serve a range of life science applications including biopharmaceutical manufacturing, cell therapy and cryogenic storage. Charter is a single site company based in Winston-Salem, North Carolina.

As at 31 December 2014, unaudited gross assets acquired were US$6.9m with underlying EBITDA (1) of US$3.3m for the 12 months to 31 December 2014 on sales of US$19.6m.Β 

The entire workforce of Charter have become employees of Fenner upon completion and will continue to be led by General Manager, Mr. Gael Peron.

Nick Hobson, CEO of Fenner PLC, commented:

"In common with all businesses in our AEP division, Charter applies its polymer technology to solving problems in performance-critical applications. Charter has a strong, established business in blood transfusion and filtration markets and has exciting opportunities in the bio-processing and regenerative medicine markets, in which Fenner is already active and which are experiencing rapid growth.Β 

The acquisition of Charter, which will provide an attractive addition to the capabilities and offerings of Solesis, continues Fenner's strategy to develop our medical business both organically and by acquisition."

For further information please contact:

Β 

Fenner PLC 01482 626501

Nick Hobson, Chief Executive

John Pratt, Finance Director

Β 

Weber Shandwick Financial 020 7067 0700

Nick Oborne / Tom Jenkins

Β 

Β 

(1) Adjusted for historic non-recurring items

Β 

Notes to editors:

Β 

Fenner PLC is a world leader in reinforced polymer technology, providing local engineered solutions for performance-critical applications. The Group operates through two divisions:

Engineered Conveyor Solutions:Β the ECS division, trading under the Fenner Dunlop, Fenner and Dunlop brand names, is a recognised leader in the global conveying market. The division offers a unique, comprehensive suite of products and services, which serve the conveying needs of mining, power generation and bulk handling markets.

Advanced Engineered Products:Β the AEP division uses advanced polymeric materials and technical expertise to provide high value-added solutions to customers' most challenging engineering problems. Customers are spread across a variety of end-user segments, including oil & gas and medical which account for some 40 per cent of divisional revenue, together with construction, transportation, automation and general industrial. AEP's trading names are recognised globally and include CDI Energy Products, EGC Critical Components, Hallite, AIP Precision Machining, Fenner Precision, Fenner Drives, James Dawson, Mandals, Secant Medical and Xeridiem.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ACQUARWRVBAURAR
Date   Source Headline
19th Aug 20147:00 amRNSDirectorate Change
6th Aug 20142:13 pmRNSDirector/PDMR Shareholding
6th Aug 201410:33 amRNSDirector/PDMR Shareholding
16th Jul 20147:00 amRNSInterim Management Statement
30th Jun 20143:06 pmRNSHolding(s) in Company
20th Jun 201412:40 pmRNSHolding(s) in Company
12th Jun 20147:00 amRNSCapital Markets Event
6th Jun 201411:20 amRNSDirector/PDMR Shareholding
5th Jun 20141:43 pmRNSDirector/PDMR Shareholding
30th May 20147:00 amRNSTrading Update
24th Apr 20144:10 pmRNSHolding(s) in Company
23rd Apr 20147:00 amRNSHalf Yearly Report
15th Apr 201412:17 pmRNSHolding(s) in Company
2nd Apr 20142:02 pmRNSHolding(s) in Company
13th Mar 20149:34 amRNSHolding(s) in Company
11th Mar 20147:00 amRNSPre-Close Trading Statement
5th Mar 20143:47 pmRNSHolding(s) in Company
3rd Mar 201410:49 amRNSBlocklisting Interim Review
20th Feb 20142:47 pmRNSHolding(s) in Company
4th Feb 20149:59 amRNSDirector/PDMR Shareholding
31st Jan 201412:28 pmRNSHolding(s) in Company
24th Jan 20142:40 pmRNSHolding(s) in Company
23rd Jan 201412:21 pmRNSHolding(s) in Company
17th Jan 20141:36 pmRNSResult of AGM
15th Jan 20147:00 amRNSInterim Management Statement
12th Dec 201310:49 amRNSDocuments Available for Inspection/Notice of AGM
29th Nov 20139:24 amRNSTotal Voting Rights
25th Nov 20139:16 amRNSDirector/PDMR Shareholding
21st Nov 20133:39 pmRNSDirector/PDMR Shareholding
14th Nov 201311:27 amRNSAdditional Listing
13th Nov 201310:15 amRNSAmendment
13th Nov 20137:00 amRNSFinal Results
8th Nov 20132:25 pmRNSHolding(s) in Company
21st Oct 20132:35 pmRNSHolding(s) in Company
27th Sep 20132:38 pmRNSHolding(s) in Company
10th Sep 20137:00 amRNSPre-close Trading Statement
2nd Sep 20132:01 pmRNSBlocklisting Interim Review
28th Aug 201311:35 amRNSHolding(s) in Company
22nd Aug 201312:16 pmRNSHolding(s) in Company
7th Aug 20134:35 pmRNSHolding(s) in Company
31st Jul 201312:38 pmRNSHolding(s) in Company
18th Jul 20137:00 amRNSInterim Management Statement
10th Jul 20139:21 amRNSHolding(s) in Company
9th Jul 20132:10 pmRNSHolding(s) in Company
5th Jul 20133:14 pmRNSHolding(s) in Company
21st Jun 201310:05 amRNSDirector/PDMR Shareholding
10th Jun 201310:50 amRNSDirector/PDMR Shareholding
5th Jun 201310:55 amRNSDirector/PDMR Shareholding
30th May 20132:33 pmRNSDirector/PDMR Shareholding
24th May 20133:46 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.